575 related articles for article (PubMed ID: 15972957)
1. Aberrant beta-catenin signaling in tuberous sclerosis.
Mak BC; Kenerson HL; Aicher LD; Barnes EA; Yeung RS
Am J Pathol; 2005 Jul; 167(1):107-16. PubMed ID: 15972957
[TBL] [Abstract][Full Text] [Related]
2. The tuberin-hamartin complex negatively regulates beta-catenin signaling activity.
Mak BC; Takemaru K; Kenerson HL; Moon RT; Yeung RS
J Biol Chem; 2003 Feb; 278(8):5947-51. PubMed ID: 12511557
[TBL] [Abstract][Full Text] [Related]
3. Signaling through beta-catenin and Lef/Tcf.
Novak A; Dedhar S
Cell Mol Life Sci; 1999 Oct; 56(5-6):523-37. PubMed ID: 11212302
[TBL] [Abstract][Full Text] [Related]
4. Axin-mediated CKI phosphorylation of beta-catenin at Ser 45: a molecular switch for the Wnt pathway.
Amit S; Hatzubai A; Birman Y; Andersen JS; Ben-Shushan E; Mann M; Ben-Neriah Y; Alkalay I
Genes Dev; 2002 May; 16(9):1066-76. PubMed ID: 12000790
[TBL] [Abstract][Full Text] [Related]
5. Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling.
Tee AR; Fingar DC; Manning BD; Kwiatkowski DJ; Cantley LC; Blenis J
Proc Natl Acad Sci U S A; 2002 Oct; 99(21):13571-6. PubMed ID: 12271141
[TBL] [Abstract][Full Text] [Related]
6. Domains of axin involved in protein-protein interactions, Wnt pathway inhibition, and intracellular localization.
Fagotto F; Jho Eh; Zeng L; Kurth T; Joos T; Kaufmann C; Costantini F
J Cell Biol; 1999 May; 145(4):741-56. PubMed ID: 10330403
[TBL] [Abstract][Full Text] [Related]
7. Pathogenesis of tuberous sclerosis subependymal giant cell astrocytomas: biallelic inactivation of TSC1 or TSC2 leads to mTOR activation.
Chan JA; Zhang H; Roberts PS; Jozwiak S; Wieslawa G; Lewin-Kowalik J; Kotulska K; Kwiatkowski DJ
J Neuropathol Exp Neurol; 2004 Dec; 63(12):1236-42. PubMed ID: 15624760
[TBL] [Abstract][Full Text] [Related]
8. Physiological regulation of [beta]-catenin stability by Tcf3 and CK1epsilon.
Lee E; Salic A; Kirschner MW
J Cell Biol; 2001 Sep; 154(5):983-93. PubMed ID: 11524435
[TBL] [Abstract][Full Text] [Related]
9. Signaling events downstream of mammalian target of rapamycin complex 2 are attenuated in cells and tumors deficient for the tuberous sclerosis complex tumor suppressors.
Huang J; Wu S; Wu CL; Manning BD
Cancer Res; 2009 Aug; 69(15):6107-14. PubMed ID: 19602587
[TBL] [Abstract][Full Text] [Related]
10. Tuberin phosphorylation regulates its interaction with hamartin. Two proteins involved in tuberous sclerosis.
Aicher LD; Campbell JS; Yeung RS
J Biol Chem; 2001 Jun; 276(24):21017-21. PubMed ID: 11290735
[TBL] [Abstract][Full Text] [Related]
11. Tuberous sclerosis complex tumor suppressor-mediated S6 kinase inhibition by phosphatidylinositide-3-OH kinase is mTOR independent.
Jaeschke A; Hartkamp J; Saitoh M; Roworth W; Nobukuni T; Hodges A; Sampson J; Thomas G; Lamb R
J Cell Biol; 2002 Oct; 159(2):217-24. PubMed ID: 12403809
[TBL] [Abstract][Full Text] [Related]
12. Initiation of Wnt signaling: control of Wnt coreceptor Lrp6 phosphorylation/activation via frizzled, dishevelled and axin functions.
Zeng X; Huang H; Tamai K; Zhang X; Harada Y; Yokota C; Almeida K; Wang J; Doble B; Woodgett J; Wynshaw-Boris A; Hsieh JC; He X
Development; 2008 Jan; 135(2):367-75. PubMed ID: 18077588
[TBL] [Abstract][Full Text] [Related]
13. Control of beta-catenin stability: reconstitution of the cytoplasmic steps of the wnt pathway in Xenopus egg extracts.
Salic A; Lee E; Mayer L; Kirschner MW
Mol Cell; 2000 Mar; 5(3):523-32. PubMed ID: 10882137
[TBL] [Abstract][Full Text] [Related]
14. Urokinase-type plasminogen activator (uPA) is critical for progression of tuberous sclerosis complex 2 (TSC2)-deficient tumors.
Stepanova V; Dergilev KV; Holman KR; Parfyonova YV; Tsokolaeva ZI; Teter M; Atochina-Vasserman EN; Volgina A; Zaitsev SV; Lewis SP; Zabozlaev FG; Obraztsova K; Krymskaya VP; Cines DB
J Biol Chem; 2017 Dec; 292(50):20528-20543. PubMed ID: 28972182
[TBL] [Abstract][Full Text] [Related]
15. Modulation of Wnt signaling by Axin and Axil.
Kikuchi A
Cytokine Growth Factor Rev; 1999; 10(3-4):255-65. PubMed ID: 10647780
[TBL] [Abstract][Full Text] [Related]
16. TSC2 missense mutations inhibit tuberin phosphorylation and prevent formation of the tuberin-hamartin complex.
Nellist M; Verhaaf B; Goedbloed MA; Reuser AJ; van den Ouweland AM; Halley DJ
Hum Mol Genet; 2001 Dec; 10(25):2889-98. PubMed ID: 11741832
[TBL] [Abstract][Full Text] [Related]
17. TSC1 and TSC2: genes that are mutated in the human genetic disorder tuberous sclerosis.
Sampson JR
Biochem Soc Trans; 2003 Jun; 31(Pt 3):592-6. PubMed ID: 12773162
[TBL] [Abstract][Full Text] [Related]
18. Regulation of YAP by mTOR and autophagy reveals a therapeutic target of tuberous sclerosis complex.
Liang N; Zhang C; Dill P; Panasyuk G; Pion D; Koka V; Gallazzini M; Olson EN; Lam H; Henske EP; Dong Z; Apte U; Pallet N; Johnson RL; Terzi F; Kwiatkowski DJ; Scoazec JY; Martignoni G; Pende M
J Exp Med; 2014 Oct; 211(11):2249-63. PubMed ID: 25288394
[TBL] [Abstract][Full Text] [Related]
19. Regulation of TSC2 by 14-3-3 binding.
Li Y; Inoki K; Yeung R; Guan KL
J Biol Chem; 2002 Nov; 277(47):44593-6. PubMed ID: 12364343
[TBL] [Abstract][Full Text] [Related]
20. The tuberous sclerosis complex genes in tumor development.
Mak BC; Yeung RS
Cancer Invest; 2004; 22(4):588-603. PubMed ID: 15565817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
